With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Welcome to the Center for Global Development's Press Center!
The Center for Global Development’s communications team is standing by to assist reporters on deadline. Our experts can provide analysis, commentary, data, and unique expertise on the global development and economic issues that are driving the news cycle. You can search for experts by their area of expertise here. To arrange an interview or to be added to our press list, please contact Eva Grant, press secretary, by phone or email at +1-202-416-4027 and email@example.com. For UK/European press, please contact Maya Verber at firstname.lastname@example.org.
You can subscribe here to our weekly newsletter, events invite list, and topic specific newsletters. You can also follow CGD on Twitter at @CGDev. Or send us an email with your interests and we would be happy to add you to our press lists.
More than a year ago, the World Health Organization (WHO) and other global health organizations launched the COVAX initiative, part of its broader Access to COVID-19 Tools Accelerator (ACT-A) programme to provide testing, treatment and vaccines to rich and poor countries alike. But COVAX and ACT-A are receptacles for donor money, not sources of finance. This month, ACT-A announced that it still needs $21 billion.
Prashant Yadav, a health care supply chain expert at the Center for Global Development in Washington, said the disappointing results challenge the assumption that all mRNA vaccines are alike.
“We’ve had this question mark since very start of research on mRNA vaccines,” he said. It’s possible, Dr. Yadav said, that CureVac’s design may be partly to blame for the low efficacy, not just the variants.
Although many vaccine experts had seen promise for CureVac’s shots in much of the unvaccinated world, the new results cloud their outlook.
"Rich countries could also accelerate production by removing obstacles to the free trade of vaccine supplies, as Prashant Yadav and Rebecca Weintraub argue in the Harvard Business Review. A centralized supply-chain database containing information from every country about its supplies of and demand for raw materials and manufacturing capacity could also help to reduce bottlenecks.
"Without immigration, the EU and UK could find their economies crippled by worker shortages within the next thirty years. A shift in attitudes to immigrants, as politically and socially difficult as it might be, will be necessary to head off economic disaster.
Distribution of cash instead of commodities is transforming humanitarian action. Cash distribution has grown quickly in past years and today represents roughly 20% of assistance is given.. Cash gives crisis affected populations choices and agency but it also places the sector based humanitarian architecture under stress. There is clearly a need to review the current coordination arrangements for cash assistance, but this has profound implications for the most powerful agencies in the sector.
The European Union and the UK will be short tens of millions of workers by 2050 due to an aging population and insufficient levels of migration, according to a new study from the Center for Global Development.